Marco Alessandrini
Biographic Data
| ID | 7638633 |
|---|---|
| NAME | Marco Alessandrini |
| GIVEN NAMES | Marco |
| FAMILY NAME | Alessandrini |
| SIGNATURE | ALESSANDRINI M |
| AFFILIATIONS | ASL Roma |
| ORCID | 0000-0002-2821-4620 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Treatment effectiveness and preference in patients with schizophrenia switched from oral standard of care atypical antipsychotics to aripiprazole once-monthly: A brief report over a six-month period
Transitioning to AOM from oral antipsychotics in schizophrenia patients was associated with significant improvements in clinical outcomes, symptom severity, and treatment satisfaction, with a favorable safety and tolerability profile. These findings support the use of AOM in early-stage schizophrenia and highlight its potential to enhance long-term adherence and functional recovery. Further long-term studies are warranted to assess the durability…
Understanding the Complex of Suicide in Depression: From Research to Clinics
Objective Amongst psychiatric disorders, major depressive disorder (MDD) is the most prevalent, by affecting approximately 15–17% of the population and showing a high suicide risk rate equivalent to around 15%. The present comprehensive overview aims at evaluating main research studies in the field of MDD at suicide risk, by proposing as well as a schematic suicide risk stratification and useful flow-chart for planning suicide preventive and ther…
No prominent works on this page.
Understanding the Complex of Suicide in Depression: From Research to Clinics
Objective Amongst psychiatric disorders, major depressive disorder (MDD) is the most prevalent, by affecting approximately 15–17% of the population and showing a high suicide risk rate equivalent to around 15%. The present comprehensive overview aims at evaluating main research studies in the field of MDD at suicide risk, by proposing as well as a schematic suicide risk stratification and useful flow-chart for planning suicide preventive and ther…
Treatment effectiveness and preference in patients with schizophrenia switched from oral standard of care atypical antipsychotics to aripiprazole once-monthly: A brief report over a six-month period
Transitioning to AOM from oral antipsychotics in schizophrenia patients was associated with significant improvements in clinical outcomes, symptom severity, and treatment satisfaction, with a favorable safety and tolerability profile. These findings support the use of AOM in early-stage schizophrenia and highlight its potential to enhance long-term adherence and functional recovery. Further long-term studies are warranted to assess the durability…
Antipsychotic (1 works) · Aripiprazole (1 works) · Clinical Psychology (1 works) · Clinical trial (1 works) · Cognition (1 works) · Family Caregiving in Mental Illness (1 works) · Healthcare Decision-Making and Restraints (1 works) · Major depressive disorder (1 works) · Medical emergency (1 works) · Medicine (1 works)